Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC)

被引:110
作者
Doktorovova, Slavomira [1 ]
Araujo, Joana [2 ]
Garcia, Marisa L. [2 ]
Rakovsky, Erik [3 ]
Souto, Eliana B. [1 ,4 ]
机构
[1] Fernando Pessoa Univ, Fac Hlth Sci, P-4200150 Oporto, Portugal
[2] Univ Barcelona, Fac Pharm, Dept Phys Chem, Inst Nanosci & Nanotechnol, E-08028 Barcelona, Spain
[3] Comenius Univ, Fac Nat Sci, Dept Inorgan Chem, Bratislava 84325, Slovakia
[4] UTAD, CGB, IBB, P-5000801 Vila Real, Portugal
关键词
Nanostructured lipid carriers; NLC; Fluticasone propionate; Polyethylene glycol; Corticosteroids; Lipid matrix; Topical administration; NANOPARTICLES SLN; TOPICAL GLUCOCORTICOIDS; DELIVERY; SPECTROSCOPY; RELEASE;
D O I
10.1016/j.colsurfb.2009.09.033
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The aim of this study was to develop nanostructured lipid carriers (NLC) for topical delivery of fluticasone propionate (FP) with the aim to further improve the safety profile and decrease the adverse-side effects commonly reported in topical corticotherapy. NLC are colloidal drug-carriers consisting of a blend of a solid lipid and a small amount of liquid lipid since these carriers have proved to be effective in epidermal targeting in particular of glucocorticoids. NLC consisting of glyceryl palmito-stearate, and PEG-containing medium chain triglycerides mixture, stabilised by polysorbate 80 and soybean phosphatidylcholine were prepared. A mean particle size between 380 and 408 nm and entrapment efficacy of 95% were obtained for FP-loaded NLC. The crystallinity and polymorphic phase behaviour of FP-free and FP-loaded NLC were examined by differential scanning calorimetry and wide angle X-ray diffraction. Results revealed a low-crystalline structure and confirmed the incorporation of FP into the particles. The suitability of PEG-containing liquid lipids to form the lipid matrix of NLC was also confirmed. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:538 / 542
页数:5
相关论文
共 29 条
[1]   Topical treatments in psoriasis: today and tomorrow [J].
Bos, Jan D. ;
Spuls, Phyllis I. .
CLINICS IN DERMATOLOGY, 2008, 26 (05) :432-437
[2]   Crystallization tendency and polymorphic transitions in triglyceride nanoparticles [J].
Bunjes, H ;
Westesen, K ;
Koch, MHJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 129 (1-2) :159-173
[3]  
BUNJES H, 2001, PROCESSES FATS LIPID, P457
[4]   Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC) [J].
Fang, Jia-You ;
Fang, Chia-Lang ;
Liu, Chi-Hsien ;
Su, Yu-Han .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 70 (02) :633-640
[5]   Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase [J].
Freitas, C ;
Müller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (02) :125-132
[6]   Physical and thermal characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets [J].
Hamdani, J ;
Moës, AJ ;
Amighi, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (01) :47-57
[7]   Preparation and characteristics of monostearin nanostructured lipid carriers [J].
Hu, Fu-Qiang ;
Jiang, Sai-Ping ;
Du, Yong-Zhong ;
Yuan, Hong ;
Ye, Yi-Qing ;
Zeng, Su .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 314 (01) :83-89
[8]   Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and raman spectroscopy [J].
Jores, K ;
Haberland, A ;
Wartewig, S ;
Mäder, K ;
Mehnert, W .
PHARMACEUTICAL RESEARCH, 2005, 22 (11) :1887-1897
[9]   Nanostructured lipid carrier (NLC) based gel of celecoxib [J].
Joshi, Medha ;
Patravale, Vandana .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 346 (1-2) :124-132
[10]   Topical therapy in pediatric atopic dermatitis [J].
Krakowski, Andrew C. ;
Dohil, Magdalene A. .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2008, 27 (02) :161-167